Outset Medical, the medical technology company responsible for the Tablo haemodialysis system, has presented five new abstracts that promise insights on the clinical and financial benefits of home haemodialysis (HHD), gender biases toward female nephrologists and other topics related to kidney disease at the National Kidney Foundation (NKF) Spring Clinical Meetings 2023 (11–15 April, Austin, USA).
“Our latest studies demonstrate how Outset is working to bring innovation to the dialysis industry by overcoming the bias that chronic kidney disease (CKD) patients need perfect conditions to treat at home,” said Michael Aragon (End Stage Renal Disease Network 14, Dallas, USA), chief medical officer for Outset. “One example is the successful implementation of Tablo in a program for an underserved population in Hawaii that overcame the challenges of environmental barriers and other health factors, resulting in a high treatment success rate.”
An Outset press release sets out that the following abstracts were presented at the event:
Redefining Dialysis Care on the Hawaiian Islands: Reducing Health Disparities and Resource Utilization: An HHD program implemented on the islands of Maui, Hawaii and Oahu where Tablo was provided for end-stage kidney disease (ESKD) care under challenging environmental conditions and among a population with the highest rates of diabetes, coronary artery disease and kidney disease of any racial group. Use of Tablo among this population resulted in a high treatment success rate even given the less than ideal home environments and patients with health disparities.
The Transition from Peritoneal Dialysis (PD) to Home Haemodialysis at Hospital Discharge: This case study focuses on the successful transition from PD to HHD using Tablo and how it can be done successfully. Once patients are performing dialysis at home, they can continue treating at home, even if they initially began dialysis in a hospital urgent-start setting.
Gender Biases in Nephrology: A 2022 Survey of Female Nephrologists: Survey results show that women in nephrology believe much more is needed to close the existing gender gap that prevents women from reaching leadership roles and equitable pay. Those surveyed weighed in on the need for female mentors, a better cultural environment in the workplace and improved work-life integration. Only 6.7% of respondents were confident that change would happen, so broader initiatives are required.
Home Haemodialysis Can Help Reduce Total Cost of Care among Medicare Advantage Members with ESRD: HHD use is increasing in the USA, but use is lowest among patients with Medicare Advantage (MA) compared to original Medicare fee-for-service without Medicaid. This abstract estimates the costs for a MA health plan and the five-year savings generated by incentivising home dialysis, in line with the Advancing American Kidney Health (AAKH) goal of 80% of new end-stage renal disease (ESRD) patients to initiate on home dialysis or with a pre-emptive transplant. This modelled analysis of 500 MA dialysis members shows estimated cost savings of US$4.2m by MA health plans through HHD expansion with innovative home dialysis technologies.
Home Haemodialysis Can Help Providers Reduce Total Cost of Care in Risk-Based Contracts with Medicare Advantage (MA) Organizations: Modeled analysis showing costs for a dialysis population from a MA health plan and the five-year savings generated by establishing a home dialysis program. Using parameters of 500 MA dialysis members, analysis shows estimated total savings of US$10.7m over five years due to lower insourced cost of dialysis and reduced event rates compared to in-clinic haemodialysis.
The press release adds that the abstracts can be read in their entirety on the Outset Medical clinical evidence page.